MEI Pharma, Inc.

NASDAQ:MEIP

3.06 (USD) • At close November 4, 2024
Bedrijfsnaam MEI Pharma, Inc.
Symbool MEIP
Munteenheid USD
Prijs 3.06
Beurswaarde 20,388,352
Dividendpercentage 55.38%
52-weken bereik 2.61 - 7.87
Industrie Biotechnology
Sector Healthcare
CEO Mr. David M. Urso B.A., Esq., J.D.
Website https://www.meipharma.com

An error occurred while fetching data.

Over MEI Pharma, Inc.

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as

Vergelijkbare Aandelen

Pro-Dex, Inc. logo

Pro-Dex, Inc.

PDEX

40.63 USD

Hepion Pharmaceuticals, Inc. logo

Hepion Pharmaceuticals, Inc.

HEPA

0.634 USD

Black Diamond Therapeutics, Inc. logo

Black Diamond Therapeutics, Inc.

BDTX

2.99 USD

Molecular Templates, Inc. logo

Molecular Templates, Inc.

MTEM

0.457 USD

Medicenna Therapeutics Corp. logo

Medicenna Therapeutics Corp.

MDNA

0.157 USD

Biotricity, Inc. logo

Biotricity, Inc.

BTCY

0.357 USD

Solid Biosciences Inc. logo

Solid Biosciences Inc.

SLDB

5.66 USD

Purple Biotech Ltd. logo

Purple Biotech Ltd.

PPBT

2.97 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)